Your browser doesn't support javascript.
Robust correlations across six SARS-CoV-2 serology assays detecting distinct antibody features.
Rowntree, Louise C; Chua, Brendon Y; Nicholson, Suellen; Koutsakos, Marios; Hensen, Luca; Douros, Celia; Selva, Kevin; Mordant, Francesca L; Wong, Chinn Yi; Habel, Jennifer R; Zhang, Wuji; Jia, Xiaoxiao; Allen, Lily; Doolan, Denise L; Jackson, David C; Wheatley, Adam K; Kent, Stephen J; Amanat, Fatima; Krammer, Florian; Subbarao, Kanta; Cheng, Allen C; Chung, Amy W; Catton, Mike; Nguyen, Thi Ho; van de Sandt, Carolien E; Kedzierska, Katherine.
  • Rowntree LC; Department of Microbiology and Immunology University of Melbourne, at the Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.
  • Chua BY; Department of Microbiology and Immunology University of Melbourne, at the Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.
  • Nicholson S; Global Station for Zoonosis Control Global Institution for Collaborative Research and Education (GI-CoRE) Hokkaido University Sapporo Hokkaido Japan.
  • Koutsakos M; Victorian Infectious Diseases Reference Laboratory The Royal Melbourne Hospital at The Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.
  • Hensen L; Department of Microbiology and Immunology University of Melbourne, at the Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.
  • Douros C; Department of Microbiology and Immunology University of Melbourne, at the Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.
  • Selva K; Victorian Infectious Diseases Reference Laboratory The Royal Melbourne Hospital at The Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.
  • Mordant FL; Department of Microbiology and Immunology University of Melbourne, at the Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.
  • Wong CY; Department of Microbiology and Immunology University of Melbourne, at the Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.
  • Habel JR; Department of Microbiology and Immunology University of Melbourne, at the Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.
  • Zhang W; Department of Microbiology and Immunology University of Melbourne, at the Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.
  • Jia X; Department of Microbiology and Immunology University of Melbourne, at the Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.
  • Allen L; Department of Microbiology and Immunology University of Melbourne, at the Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.
  • Doolan DL; Department of Microbiology and Immunology University of Melbourne, at the Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.
  • Jackson DC; Centre for Molecular Therapeutics Australian Institute of Tropical Health & Medicine James Cook University Cairns QLD Australia.
  • Wheatley AK; Department of Microbiology and Immunology University of Melbourne, at the Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.
  • Kent SJ; Global Station for Zoonosis Control Global Institution for Collaborative Research and Education (GI-CoRE) Hokkaido University Sapporo Hokkaido Japan.
  • Amanat F; Department of Microbiology and Immunology University of Melbourne, at the Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.
  • Krammer F; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology University of Melbourne Melbourne VIC Australia.
  • Subbarao K; Department of Microbiology and Immunology University of Melbourne, at the Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.
  • Cheng AC; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology University of Melbourne Melbourne VIC Australia.
  • Chung AW; Infectious Diseases Department Melbourne Sexual Health Centre Alfred Health Central Clinical School Monash University Melbourne VIC Australia.
  • Catton M; Department of Microbiology Icahn School of Medicine at Mount Sinai New York NY USA.
  • Nguyen TH; Graduate School of Biomedical Sciences Icahn School of Medicine at Mount Sinai New York NY USA.
  • van de Sandt CE; Department of Microbiology Icahn School of Medicine at Mount Sinai New York NY USA.
  • Kedzierska K; Department of Microbiology and Immunology University of Melbourne, at the Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.
Clin Transl Immunology ; 10(3): e1258, 2021.
Article in English | MEDLINE | ID: covidwho-1107626
ABSTRACT

OBJECTIVES:

As the world transitions into a new era of the COVID-19 pandemic in which vaccines become available, there is an increasing demand for rapid reliable serological testing to identify individuals with levels of immunity considered protective by infection or vaccination.

METHODS:

We used 34 SARS-CoV-2 samples to perform a rapid surrogate virus neutralisation test (sVNT), applicable to many laboratories as it circumvents the need for biosafety level-3 containment. We correlated results from the sVNT with five additional commonly used SARS-CoV-2 serology techniques the microneutralisation test (MNT), in-house ELISAs, commercial Euroimmun- and Wantai-based ELISAs (RBD, spike and nucleoprotein; IgG, IgA and IgM), antigen-binding avidity, and high-throughput multiplex analyses to profile isotype, subclass and Fc effector binding potential. We correlated antibody levels with antibody-secreting cell (ASC) and circulatory T follicular helper (cTfh) cell numbers.

RESULTS:

Antibody data obtained with commercial ELISAs closely reflected results using in-house ELISAs against RBD and spike. A correlation matrix across ten measured ELISA parameters revealed positive correlations for all factors. The frequency of inhibition by rapid sVNT strongly correlated with spike-specific IgG and IgA titres detected by both commercial and in-house ELISAs, and MNT titres. Multiplex analyses revealed strongest correlations between IgG, IgG1, FcR and C1q specific to spike and RBD. Acute cTfh-type 1 cell numbers correlated with spike and RBD-specific IgG antibodies measured by ELISAs and sVNT.

CONCLUSION:

Our comprehensive analyses provide important insights into SARS-CoV-2 humoral immunity across distinct serology assays and their applicability for specific research and/or diagnostic questions to assess SARS-CoV-2-specific humoral responses.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Diagnostic study Topics: Vaccines Language: English Journal: Clin Transl Immunology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Diagnostic study Topics: Vaccines Language: English Journal: Clin Transl Immunology Year: 2021 Document Type: Article